Phibro Animal Health Corporation (PAHC)
PAHC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1069899/000110465926101493/0001104659-26-101493-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | PAHC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001069899 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $1.5B |
| Net income | $99.7M |
| Operating income | $194.4M |
| Net margin | 6.6% |
| Operating margin | 12.8% |
| Revenue growth | +17.1% |
| Cash | $61.4M |
| Total assets | $1.5B |
| P/E (computed) | 14.3× |
| P/S (computed) | 0.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $75.5M cash; operating cash flow $21.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 40,601,603 (2026-10-30); 40,533,608 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Florham Park, New Jersey, United States | PCAOB Form AP 2026-09-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $318K, sold $30.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | $386.8M | $29.5M | $26.1M | $75.5M | $610.9M | $1.5B | 10-Q 2026-11-04 |
| Q4 2026 2026-06-30 | $396.7M | $21.7M | $24.1M | $61.4M | $616.8M | $1.5B | 10-K 2026-08-26 |
| Q3 2026 2026-03-31 | $383.5M | $24.0M | $16.2M | $54.9M | $620.5M | $1.5B | 10-Q 2026-05-06 |
| Q2 2026 2025-12-31 | $373.9M | $27.5M | $19.4M | $55.5M | $624.2M | $1.5B | 10-Q 2026-02-04 |
| Q1 2026 2025-09-30 | $363.9M | $26.5M | $9.3M | $72.8M | $628.0M | $1.4B | 10-Q 2026-11-04 |
| Q4 2025 2025-06-30 | $378.7M | $17.2M | $21.3M | $68.0M | $631.7M | $1.3B | 10-K 2026-08-26 |
| Q3 2025 2025-03-31 | $347.8M | $20.9M | $43.2M | $60.4M | $635.4M | $1.2B | 10-Q 2026-05-06 |
| Q2 2025 2024-12-31 | $309.3M | $3.2M | $3.1M | $67.1M | $639.1M | $1.1B | 10-Q 2026-02-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FINAL PROSPECTUS | 424B4 | 2014-04-14 |
| Latest annual report | 10-K | 2026-08-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-09-18 |
Source: SEC EDGAR submissions feed, 774 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +9.1% |
| 1 month | -2.3% |
| 3 months | +5.6% |
| Year to date | -3.7% |
| 1 year | -19.5% |
| From 52-week high | -39.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NBTX | Nanobiotix S.A. | $28.54 | -6.90% | $1.5B |
| DMRA | Damora Therapeutics Inc. | $22.50 | +4.14% | $1.4B |
| LBRX | LB Pharmaceuticals Inc | $42.99 | -0.05% | $1.4B |
| PCRX | Pacira BioSciences Inc. | $36.48 | +0.05% | $1.5B |
| URGN | UroGen Pharma Ltd. | $28.10 | +7.33% | $1.4B |
| RAPP | Rapport Therapeutics Inc. | $24.82 | -5.09% | $1.5B |
| TYRA | Tyra Biosciences Inc. | $19.74 | -1.42% | $1.4B |
| ANAB | AnaptysBio Inc. | $45.73 | -1.12% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier